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W. J. F. M. van der Velden, J. P. Donnelly, N. M. A. BlijlevensThe role of innate immunity is increasingly prom-
inent in stem cell transplantation (SCT) and has re-
cently been reviewed by Penack et al. [1]. This has
been largely due to the recognition of a role for genetic
variations, mainly single nucleotide polymorphisms
(SNPs), in innate immune genes impacting the out-
come of SCT regarding infections, graft-versus-host
disease (GVHD), and treatment-related mortality
(TRM) [2]. The landmark study ofHoller et al. showed
that NOD2 polymorphisms do increase the risk for
acute GVHD (aGVHD) and TRM in matched related
SCT and was a breakthrough in the field of non-HLA
genetics in SCT (Figure 1A) [3]. However, confusion
arose when several others were unable to confirm the
strong clinical manifestations of these polymorphisms.
This underscored the fact that the influence of innate
immune gene SNPs depends on the context. For in-
stance, the absence of a strong effect of NOD2 SNPs
on aGVHD in the setting of matched unrelated donor
SCT seemed largely dependent on the use of T cell de-
pletion in vivo with alemtuzumab or antithymocyte
globulin (ATG) (Figure 1B) [4]. Others have argued
that the high incidence of GVHD in unrelated donor
transplants ‘‘overrules’’ the effects of NOD2 polymor-
phisms, and that reducing the incidence of GVHD us-
ing T cell depletion might again reveal their effects
(Figure 1C) [5,6]. Ex vivo T cell depletion in
matched related SCT was also shown to reduce the
impact of NOD2 polymorphisms simply due to the
reduction of the overall incidence of aGVHD [7].
However, we disputed these findings by showing an
impact of NOD2 in a similar cohort of patients, and
we suggested that the use of a more intensive condi-
tioning regimen, which includes idarubicin, induces
more intestinal damage and corresponding inflamma-
tion that had actually boosted GVHD despite theDepartment of Hematology, Radboud University
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phism visible once more (Figure 1D) [8].
In a recent issue of this journal, van der Straaten et al.
published the first large study on the impact of NOD2
polymorphisms in the setting of nonmyeloablative SCT
achieved using low-dose total body irridiation (TBI)
with or without fludarabine. They showed that NOD2
polymorphisms had no impact on aGVHD and chronic
GVHD (cGVHD), TRM, or relapse [9]. A considerable
number of patients received ATG, but their result might
not only be explained by the use of in vivo T cell deple-
tion, but also by the absence of intestinal damage.
Recently, we showed there was a strong correlation
betweenthe intestinaldamage inducedbyamyeloablative
conditioning regimen and the ensuing inflammatory
response, the early onset of aGVHD (mean day 25) and
more severe aGVHD, even in the ex vivo T cell depleted
setting [10].This is in linewith the three-phasepathogen-
esismodel ofGVHD,which emphasizes the role of tissue
damage, especially of the intestine, and the concomitant
‘‘cytokine storm’’ in initiating GVHD [11]. By contrast,
we showed that nonmyeloablative conditioning lead
only to limited intestinal damage that was not accompa-
nied by an early inflammatory response. This resulted
in a delay of aGVHD (mean day 40) (Figure 1E) [10].
Similar results were shown in a mouse model where the
use of reduced intensity conditioning led to less tissue
damage that influenced the occurrence and timing of
GVHD [12]. The impact of NOD2 most likely occurs
early, that is, during the phase of conditioning-induced
intestinalmucositis, because ithasbeenshownthat theef-
fects of NOD2 polymorphisms involve mainly altered
host antigen-presenting cells (APCs) function, deregu-
latedmucosal immunity, andperturbedhost–microbe in-
teractions [1,13]. The priming and activation of APCs
directly by chemotherapy and radiotherapy, and
indirectly by the release of cytokines and translocation
of microbial product through the intestinal wall during
mucositis, has been demonstrated as pivotal in the
occurrence of early aGVHD [14,15]. So reduced
intestinal damage resulting from the use of
nonmyeloablative conditioning might negate the
impact of SNPs in innate immune genes, including
NOD2. Although van der Straaten et al. did not
measure oral and intestinal mucositis, we believe that1421
Figure 1. The course of intestinal damage, inflammation, and T cell recovery differs among SCT settings and influences the role of NOD2 polymor-
phisms in aGVHD.
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Figure 2. Factors influencing the impact of NOD2 polymorphism on aGVHD.
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resulted in attenuated mucositis or even none at all,
which, at least in part, might have explained the
absence of an impact of NOD2 polymorphisms in their
cohort (Figure 1E). This being the case, it might prove
useful to extend the classification of myeloablative, non-
myeloablative, or reduced-intensity conditioning (RIC)
regimens to include their capacity for inducing intestinal
mucositis, for instance, bymeasuring the course of serum
or plasma citrulline [16].
In summary, the specific characteristics of a partic-
ular SCT setting, such as the use of ex vivo or in vivo T
cell depletion and the extent of intestinal mucositis in-
duced by the conditioning regimen, largely determines
the dynamics of aGVHD rather than innate immune
genes per se (Figure 1). Matters including the use of
ex vivo or in vivo T cell depletion and the extent of in-
testinal mucositis induced by the conditioning regi-
mens should be considered when interpreting results
on genetic association in SCT, as should many other
factors as depicted in Figure 2.ACKNOWLEDGMENTS
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